{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:47:29Z","timestamp":1788648449573,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40256-023-00620-6","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T08:02:11Z","timestamp":1703750531000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct01776424","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-7621","authenticated-orcid":false,"given":"Andre","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant I.","family":"Bangdiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles R.","family":"Dagenais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley R. H.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jhih","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Probstfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the COMPASS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"620_CR1","doi-asserted-by":"crossref","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol. 2020;76:2982\u20133021.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"620_CR2","unstructured":"American Heart Association. Cardiovascular disease: A costly burden for America projections through 2035. 2017. Available online from  https:\/\/www.heart.org\/-\/media\/Files\/About-Us\/Policy-Research\/Fact-Sheets\/Public-Health-Advocacy-and-Research\/CVD-A-Costly-Burden-for-America-Projections-Through-2035.pdf. Accessed December 23, 2023."},{"key":"620_CR3","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al., on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319\u201330.","DOI":"10.1056\/NEJMoa1709118"},{"key":"620_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ehjqcco\/qcac054","volume":"9","author":"A Lamy","year":"2023","unstructured":"Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang W-J, Bhatt DL, Probstfield J, Ertl G, St\u00f6rk S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. 2023;9:502\u201310.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"620_CR5","doi-asserted-by":"crossref","unstructured":"Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol. 2017;33:1027\u201335.","DOI":"10.1016\/j.cjca.2017.06.001"},{"key":"620_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M, Schulpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. UK: Oxford Medical Publication; 2005.","edition":"3"},{"key":"620_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cjca.2011.08.112","volume":"28","author":"A Lamy","year":"2012","unstructured":"Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012;28:95\u2013101.","journal-title":"Can J Cardiol"},{"key":"620_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jdiacomp.2014.02.012","volume":"28","author":"A Lamy","year":"2014","unstructured":"Lamy A, Tong W, Jung H, Gafni A, Singh K, Tyrwhitt J, Yusuf S, Gerstein HC, ORIGIN Investigators. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complications. 2014;28:553\u20138.","journal-title":"J Diabetes Complications"},{"key":"620_CR9","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.athoracsur.2014.06.046","volume":"98","author":"A Lamy","year":"2014","unstructured":"Lamy A, Tong W, Devereaux PJ, Gao P, Gafni A, Singh K, Taggart D, Straka Z, Akar AR, Piegas L, Ou Y, Yusuf S. The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. Ann Thorac Surg. 2014;98:1620\u20135.","journal-title":"Ann Thorac Surg"},{"key":"620_CR10","doi-asserted-by":"crossref","unstructured":"Anderson JL, Heidenreich PA, Barnett PG, et al. ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304\u201322.","DOI":"10.1016\/j.jacc.2014.03.016"},{"key":"620_CR11","unstructured":"Institute for Clinical and Economic Review. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Economic Review; 2019. Available at https:\/\/icer-review.org\/wp-content\/uploads\/2019\/02\/ICER_CVD_Draft_Evidence_Report_072419.pdf. Accessed April 22, 2020."},{"key":"620_CR12","unstructured":"MEDPAR\u2014Centers for Medicare & Medicaid Services. Available at https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/MedicareFeeforSvcPartsAB\/MEDPAR.html. Accessed October 30, 2018."},{"key":"620_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3111\/13696998.2011.627405","volume":"14","author":"A Lamy","year":"2011","unstructured":"Lamy A, Wang X, Gao P, Tong W, Gafni A, Dans A, Avezum A, Ferreira R, Young J, Yusuf S, Teo K, ONTARGET Investigators. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. J Med Econ. 2011;14:792\u20137.","journal-title":"J Med Econ"},{"key":"620_CR14","doi-asserted-by":"crossref","unstructured":"Yuan F, Bangdiwala S, Tong W, Lamy A. Projecting effectiveness after ending a randomized controlled trial: A two-state Markov microsimulation model. Int J Technol Assess Health Care. 2020:1\u20138.","DOI":"10.1017\/S0266462320000446"},{"issue":"1","key":"620_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/14737167.2023.2144838","volume":"23","author":"F Yuan","year":"2022","unstructured":"Yuan F, Bangdiwala SI, Tong W, Lamy A. The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices. Expert Rev Pharmacoecon Outcomes Res. 2022;23(1):69\u201378.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"620_CR16","unstructured":"Arias E, Heron M, Xu J. United States Life Tables, 2013. Natl Vital Stat Rep. 2017 Apr;66(3):1-64. PMID: 28437241."},{"key":"620_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322\u201338.","journal-title":"Med Decis Making"},{"key":"620_CR18","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409\u201321.","journal-title":"Stat Med"},{"key":"620_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol"},{"key":"620_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"key":"620_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203\u201320.","journal-title":"Med Care"},{"key":"620_CR22","unstructured":"NICE. Developing NICE guidelines: the manual | Guidance and guidelines|NICE. Available at https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/incorporating-economic-evaluation. Accessed November 5, 2018."},{"key":"620_CR23","unstructured":"Bioethics and Disability Report Series. Available at https:\/\/ncd.gov\/. Accessed September 27, 2023."},{"key":"620_CR24","unstructured":"Cost-Effectiveness, the QALY, and the evLYG. ICER. Available at https:\/\/icer.org\/our-approach\/methods-process\/cost-effectiveness-the-qaly-and-the-evlyg\/. Accessed September 27, 2023."},{"key":"620_CR25","unstructured":"Demystifying ICER\u2019s equal value of life years gained metric. ISPOR | International Society For Pharmacoeconomics and Outcomes Research. Available at https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/overcoming-vaccine-hesitancy-injecting-trust-in-the-community\/demystifying-icer-s-equal-value-of-life-years-gained-metric. Accessed September 27, 2023."},{"key":"620_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/hec.1730","volume":"21","author":"M Paulden","year":"2012","unstructured":"Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Health Econ. 2012;21:612\u20138.","journal-title":"Health Econ"},{"key":"620_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PWF Wilson","year":"2012","unstructured":"Wilson PWF, D\u2019Agostino R, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liau C-S, Ohman EM, R\u00f6ther J, Reid C, Mas J-L, Steg PG, REACH Registry. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695-703.e1.","journal-title":"Am J Med"},{"key":"620_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","volume":"270","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol. 2018;270:54\u20139.","journal-title":"Int J Cardiol"},{"key":"620_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/2047487318817910","volume":"26","author":"E Zomer","year":"2019","unstructured":"Zomer E, Si S, Hird TR, Liew D, Owen AJ, Tonkin A, Reid CM, Ademi Z. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective. Eur J Prev Cardiol. 2019;26:858\u201368.","journal-title":"Eur J Prev Cardiol"},{"key":"620_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz278","author":"MR Cowie","year":"2019","unstructured":"Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere J-B. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2019. https:\/\/doi.org\/10.1093\/cvr\/cvz278.","journal-title":"Cardiovasc Res"},{"key":"620_CR31","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/13696998.2021.1997024","volume":"24","author":"JA Spoorendonk","year":"2021","unstructured":"Spoorendonk JA, Briere J-B, Bowrin K, Millier A, Coppens M, Tempelaar S, Verheggen B. Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. J Med Econ. 2021;24:1231\u20139.","journal-title":"J Med Econ"},{"key":"620_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40261-021-01023-8","volume":"41","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG. Cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in Italy. Clin Drug Investig. 2021;41:459\u201368.","journal-title":"Clin Drug Investig"},{"key":"620_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.921387","volume":"13","author":"T Feng","year":"2022","unstructured":"Feng T, Zheng Z, Gao S, Xu J, Cao P, Jia H, Yu X. Cost-effectiveness analysis of rivaroxaban in Chinese patients with stable cardiovascular disease. Front Pharmacol. 2022;13: 921387.","journal-title":"Front Pharmacol"},{"key":"620_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10557-020-07059-w","volume":"35","author":"M-C Lee","year":"2021","unstructured":"Lee M-C, Liao C-T, Toh HS, Chou C-C, Chang W-T, Chen Z-C, Wu W-S, Yu T, Strong C. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. Cardiovasc Drugs Ther. 2021;35:539\u201347.","journal-title":"Cardiovasc Drugs Ther"},{"key":"620_CR35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","volume":"1","author":"TA Gaziano","year":"2016","unstructured":"Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJV, Solomon SD. Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666\u201372.","journal-title":"JAMA Cardiol."},{"key":"620_CR36","unstructured":"House TW. FACT SHEET: Biden-Harris Administration Announces First Ten Drugs Selected for Medicare Price Negotiation. The White House. Available at https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2023\/08\/29\/fact-sheet-biden-harris-administration-announces-first-ten-drugs-selected-for-medicare-price-negotiation\/. Accessed September 19, 2023."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00620-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:30:26Z","timestamp":1706013026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00620-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00620-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"20 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The COMPASS clinical trial was funded by Bayer; however, no direct funding was allocated for this analysis. The authors had free access to the complete study data and performed all analysis independently of the sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AL, WT, FY, SB, LD, GRD, WJW, and JP have no conflicts to report. JE reports grants and personal fees from Bayer, Boehringer Ingelheim, Briston-Myers Squibb\/Pfizer, Daiichi Sankyo, Janssen, Astra Zeneca, Eli Lilly, GlaxoSmithKlein and Sanofi Aventis. JB reports grants from Bayer. SC reports grants from Bayer AG and personal fees from BMS, Pfizer, Portola, Boehringer Ingelheim, Servier, Daiichi Sankyo and Medtronic. EL reports personal fees from Bayer, Amgen, Sanofi, Novartis and Servier. KRHB reports grants from Bayer and Astellas and other fees from Janssen. DLB discloses the following relationships: Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys; Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock); Consultant: Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald\u2019s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo. GE reports grants from Bayer. SS reports grants from Bayer, Servier, Boehringer Ingelheim, Novartis and Thermo Fisher as well as personal fees from Novartis, Thermo Fisher and Pfizer. PGS reports grants from PHRI, Sanofi and Servier as well as personal fees from PHRI, Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Lilly, Merck Sharpe-Dohme, Novartis, Pfizer, Sanofi, Servier, Janssen, CSL Behring and Regeneron. VA reports honoraria from Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Pfizer\/Bristol-Myers Squibb alliance, and Merck Sharp and Dohme. IDZ reports personal fees from BMS, Pfizer, MSD, Sanofi, Medtronic, Boston Scientific and Amgen. LR reports grants from the Swedish Heart Lung Foundation, Swedish Diabetes Foundation, Amgen, Bayer AG, Boehringer Ingelheim, MSD and Novo Nordisk as well as personal fees from Boehringer Ingelheinm MSD and Novo Nordisk. SY reports grants and personal fees from Bayer, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb and Cadila.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Andre Lamy: conceptulization, methodology, investigation, data curation, writing\u2014review and editing, visualization and supervision. John Eikelboom: investigation and writing\u2014review and editing. Wesley Tong: conceptulization, methodology, investigation and writing\u2014original draft. Fei Yuan: methodology, software, validation, formal analysis and writing\u2014review and editing. Shrikant I. Bangdiwala: methodology and writing\u2014review and editing. Jackie Bosch: investigation and writing\u2014review and editing. Stuart Connolly: writing\u2014review and editing. Eva Lonn: writing\u2014review and editing. Gilles R. Dagenais: writing\u2014review and editing. Kelley R.H. Branch: investigation and writing\u2014review and editing. Wei-Jhih Wang: investigation and writing\u2014review and editing. Deepak L Bhatt: writing\u2014review and editing. Jeff Probstfield: writing\u2014review and editing. Georg Ertl: investigation, writing\u2014review and editing. Stefan Stork: investigation and writing\u2014review and editing. Victor Aboyans: investigation and writing\u2014review and editing. Isabelle Durand\u2014Zaleski: investigation and writing\u2014review and editing. Lars Ryden: writing\u2014review and editing. Salim Yusuf: investigation and writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}